Add to ORKGTreatment with dopamin agonists, particularly cabergoline, is the primary and preferred therapy for prolactinomas and symptomatic hyperprolactinaemia due to its effectiveness and tolerability. However, an association has been demonstrated between fibrotic heart valve disease and high-dose dopamin agonist use in patients with Parkinson's disease in several echocardiographic studies. Such observations have prompted a number of studies of valvular function in cabergoline-treated hyperprolactinaemia patients. These studies have failed to show an increased prevalence of clinically significant valvular regurgitation.</p
The surveillance strategy for patients taking low dose cabergoline for hyperprolactinaemia is contro...
CONTEXT Uncertainty exists whether the long-term use of ergot-derived dopamine agonist (DA) drugs fo...
CONTEXT Uncertainty exists whether the long-term use of ergot-derived dopamine agonist (DA) drugs fo...
Summary Introduction and aim: Dopamine agonists have been reported to increase the risk of cardi...
Objective The use of ergot-derived dopamine agonists (DA) to treat patients with prolactinomas has n...
OBJECTIVE: Recent trials suggest that using ergot-derived dopamine agonists such as cabergoline in t...
This is a joint position statement of the British Society of Echocardiography, the British Heart Val...
Background: There is growing evidence that ergot dopamine agonists may induce cardiac valve regurgit...
textabstractObjective: Treatment with ergot-derived dopamine agonists, pergolide, and cabergoline ha...
This is a joint position statement of the British Society of Echocardiography, the British Heart Val...
Since the 1990's cabergoline has been the treatment of choice in prolactinoma, as it permits rapid a...
Objective: Cabergoline (CAB) has been found to be associated with increased risk of cardiac valve re...
Background: There is growing evidence that ergot dopamine agonists may induce cardiac valve regurgit...
Background: There is growing evidence that ergot dopamine agonists may induce cardiac valve regurgit...
International audienceSince the 1990's cabergoline has been the treatment of choice in prolactinoma,...
The surveillance strategy for patients taking low dose cabergoline for hyperprolactinaemia is contro...
CONTEXT Uncertainty exists whether the long-term use of ergot-derived dopamine agonist (DA) drugs fo...
CONTEXT Uncertainty exists whether the long-term use of ergot-derived dopamine agonist (DA) drugs fo...
Summary Introduction and aim: Dopamine agonists have been reported to increase the risk of cardi...
Objective The use of ergot-derived dopamine agonists (DA) to treat patients with prolactinomas has n...
OBJECTIVE: Recent trials suggest that using ergot-derived dopamine agonists such as cabergoline in t...
This is a joint position statement of the British Society of Echocardiography, the British Heart Val...
Background: There is growing evidence that ergot dopamine agonists may induce cardiac valve regurgit...
textabstractObjective: Treatment with ergot-derived dopamine agonists, pergolide, and cabergoline ha...
This is a joint position statement of the British Society of Echocardiography, the British Heart Val...
Since the 1990's cabergoline has been the treatment of choice in prolactinoma, as it permits rapid a...
Objective: Cabergoline (CAB) has been found to be associated with increased risk of cardiac valve re...
Background: There is growing evidence that ergot dopamine agonists may induce cardiac valve regurgit...
Background: There is growing evidence that ergot dopamine agonists may induce cardiac valve regurgit...
International audienceSince the 1990's cabergoline has been the treatment of choice in prolactinoma,...
The surveillance strategy for patients taking low dose cabergoline for hyperprolactinaemia is contro...
CONTEXT Uncertainty exists whether the long-term use of ergot-derived dopamine agonist (DA) drugs fo...
CONTEXT Uncertainty exists whether the long-term use of ergot-derived dopamine agonist (DA) drugs fo...